Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial
NCT07921108, Not applicable, Recruiting, Chang Gung Memorial Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Web-Based Tele-Rehabilitation Using Action Observation and Mirror Therapy for Subacute Stroke: A Randomized Controlled Trial | ClinicalTrials.gov |
| NCT number | NCT07921108 | ClinicalTrials.gov |
| Status | Recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Chang Gung Memorial Hospital | ClinicalTrials.gov |
| Conditions | Stroke, Upper Extremity Paresis | ClinicalTrials.gov |
| Interventions | App-based combined action observation and mirror therapy, App-based action observation therapy | ClinicalTrials.gov |
| First posted | 2026-11-06 | ClinicalTrials.gov |
| Last updated | 2026-11-06 | ClinicalTrials.gov |
Registered outcomes 6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline in Fugl-Meyer Assessment for Upper Extremity (FMA-UE) Score | Baseline, 4 weeks (immediately post-intervention), and 12 weeks post-baseline | The Fugl-Meyer Assessment for Upper Extremity (FMA-UE) is a widely recognized, stroke-specific performance-based impairment index designed to assess upper extremity motor recovery. It evaluates voluntary movement, reflex activity, grasping, and wrist/hand coordination across 33 items. Each item is scored on a 3-point ordinal scale (0 = cannot perform, 1 = performs partially, 2 = performs fully), yielding a total score ranging from 0 to 66, with higher scores indicating better upper limb motor function. | ClinicalTrials.gov |
| Secondary | Change from Baseline in modified Rankin Scale (mRS) Score | Baseline, 4 weeks (immediately post-intervention), and 12 weeks post-baseline | The modified Rankin Scale (mRS) is a clinician-reported single-item measure of global disability and functional dependence following stroke. The scale ranges from 0 (no symptoms at all) to 6 (dead), with 0-2 indicating functional independence, 3 indicating moderate disability (requiring some help but able to walk without assistance), and 4-5 indicating severe disability and dependence. Lower scores reflect superior global functional independence. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Box and Block Test (BBT) Score | Baseline, 4 weeks (immediately post-intervention), and 12 weeks post-baseline | The Box and Block Test (BBT) evaluates gross manual dexterity by measuring the number of wooden blocks transferred one by one from one compartment of a divided box to the other within 60 seconds using the affected upper extremity. Higher scores indicate superior manual dexterity. | ClinicalTrials.gov |
| Secondary | Change from Baseline in ABILHAND Questionnaire Score | Baseline, 4 weeks (immediately post-intervention), and 12 weeks post-baseline | The ABILHAND questionnaire is a patient-reported measure of manual ability during daily bimanual activities. Patients rate their perceived difficulty on 23 representative daily manual tasks as impossible (0), difficult (1), or easy (2). Ordinal scores are converted via Rasch analysis into a linear logit measure, where higher logit scores indicate greater ease and manual capability. | ClinicalTrials.gov |
| Secondary | Change from Baseline in Short-form Quality of Movement Inventory (QMI) Score | Baseline, 4 weeks (immediately post-intervention), and 12 weeks post-baseline | The short-form Quality of Movement Inventory (QMI) assesses the qualitative performance and movement smoothness of the paretic upper limb during specific motor tasks. Higher scores denote improved quality of movement and less compensatory strategies. | ClinicalTrials.gov |
| Secondary | Telerehabilitation System Feasibility, Usability, and Training Adherence | 4 weeks (immediately post-intervention) | Feasibility, usability, and adherence are evaluated using a multi-metric approach: (1) training adherence rate, measured as the percentage of completed digital sessions relative to the prescribed 20 sessions (36 minutes daily, 5 days per week over 4 weeks) monitored via client-side breakpoint-resume tracking within the Neuro-Mirror Pro application; (2) dropout/retention rate; (3) platform usability assessed via the System Usability Scale (SUS, scored 0-100, where higher scores indicate superior usability); (4) user acceptance, perceived ease of use, and satisfaction assessed using the Technology Acceptance Model-2 (TAM-2, rated on a 5-point Likert scale) and the USE (Usefulness, Satisfaction, and Ease of Use) questionnaire (rated on a 7-point Likert scale); and (5) intervention safety, evaluated by tracking any study-related adverse events during the 4-week period. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)